Loading...
XJPX
4554
Market cap265mUSD
Dec 05, Last price  
1,690.00JPY
1D
-3.43%
1Q
7.30%
Jan 2017
25.19%
Name

Fuji Pharma Co Ltd

Chart & Performance

D1W1MN
XJPX:4554 chart
P/E
6.71
P/S
0.89
EPS
251.85
Div Yield, %
2.51%
Shrs. gr., 5y
-4.46%
Rev. gr., 5y
4.93%
Revenues
46.14b
+12.84%
14,940,538,00017,201,236,00019,701,956,00021,623,812,00021,522,065,00025,174,000,00029,215,000,00031,680,000,00034,229,000,00035,387,000,00037,909,000,00036,279,000,00033,793,000,00033,990,000,00035,426,000,00040,889,000,00046,138,000,000
Net income
6.15b
+78.92%
1,251,714,0001,525,958,0001,944,071,0002,204,846,0001,370,930,0002,068,000,0002,078,000,0002,092,000,0002,118,000,0003,301,000,0003,372,000,0002,962,000,0002,085,000,0002,432,000,0002,696,000,0003,435,000,0006,146,000,000
CFO
4.15b
+116.54%
952,631,0001,816,744,0002,168,237,0001,954,075,0001,171,679,0003,630,000,0002,757,000,000589,000,0004,509,000,0003,238,000,0003,773,000,0007,035,000,0005,770,000,0005,993,000,000-658,000,0001,917,000,0004,151,000,000
Dividend
Sep 29, 20250 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women; in vitro diagnostics, acute medical care products, and curative medicines; and information regarding pharmaceuticals and health. Fuji Pharma Co., Ltd. was incorporated in 1965 and is headquartered in Tokyo, Japan.
IPO date
Jun 22, 1995
Employees
1,560
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT